Biovica International AB logo

BIOVIC B - Biovica International AB News Story

SEK42.5 0.7  1.7%

Last Trade - 09/04/21

Sector
Healthcare
Size
Small Cap
Market Cap £102.7m
Enterprise Value £89.6m
Revenue £150k
Position in Universe 896th / 1831

BRIEF-Biovica International: Clinical Cancer Research Publishes Results Supporting DiviTum As Technology For Early Evaluation Of Metastatic Breast Cancer Treatment

Thu 16th January, 2020 7:06am
Jan 16 (Reuters) - Biovica International AB  BIOVICb.ST :
    * CLINICAL CANCER RESEARCH PUBLISHES RESULTS SUPPORTING
DIVITUM AS
A TECHNOLOGY FOR EARLY EVALUATION OF METASTATIC BREAST CANCER
TREATMENT
    * DATA SHOWS THAT DIVITUM(®) CAN BE USED TO EVALUATE
TREATMENT
EFFICACY OF A CDK 4/6 INHIBITOR IN METASTATIC BREAST CANCER
    * BIOVICA INTERNATIONAL AB - DIVITUM(®) HAS BEEN EVALUATED
IN MORE
THAN TEN STUDIES INCLUDING MORE THAN 1 700 BREAST CANCER
PATIENTS
    * RESULTS FROM THESE STUDIES PROVIDE FIRST EVIDENCE FOR
DIVITUM(®)
AS A BIOMARKER OF EFFICACY OF PALBOCICLIB IN METASTATIC BREAST
CANCER AND BUILD UPON PRIOR EVIDENCE IN PRE-OPERATIVE SETTING
    * RESULTS NEED CONFIRMATION IN LARGER, ONGOING STUDIES, AND
ARE
ENCOURAGING IN TERMS OF CLINICAL VALUE

Source text for Eikon:  ID:nWkr4b5txd 
Further company coverage:  BIOVICb.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.